CAJ | 학술논문

目的：检测PCDH10基因在肾癌组织中的甲基化状态，并分析其临床意义。方法应用甲基化特异性PCR（MSP）技术检测PCDH10基因在5株肾癌细胞系和47例肾癌组织样本中的甲基化情况，同时分析47例患者的临床资料及病理信息，进行统计研究。结果5株肾癌细胞系中有2株检出PCDH10基因甲基化，比率为40%；47例肾癌样本中有31例检出PCDH10基因甲基化，比率为66.0%，6例癌旁组织中有1例检出PCDH10基因甲基化，比率为16.7%。PCDH10基因出现甲基化的患者与未出现甲基化的患者相比，二者在性别、年龄、肿瘤部位、大小、病理核分级等指标的差异无统计学意义（P＞0.05），但在Ⅰ期肾癌与Ⅱ～Ⅲ期肾癌之间PCDH10基因甲基化率的差异有统计学意义（P＜0.05）。结论 PCDH10基因在肾癌组织中甲基化程度较高，高分期的肾癌可能具有更高的PCDH10基因甲基化率，提示PCDH10基因甲基化可能与肾癌的发生发展有关。
목적：검측PCDH10기인재신암조직중적갑기화상태，병분석기림상의의。방법응용갑기화특이성PCR（MSP）기술검측PCDH10기인재5주신암세포계화47례신암조직양본중적갑기화정황，동시분석47례환자적림상자료급병리신식，진행통계연구。결과5주신암세포계중유2주검출PCDH10기인갑기화，비솔위40%；47례신암양본중유31례검출PCDH10기인갑기화，비솔위66.0%，6례암방조직중유1례검출PCDH10기인갑기화，비솔위16.7%。PCDH10기인출현갑기화적환자여미출현갑기화적환자상비，이자재성별、년령、종류부위、대소、병리핵분급등지표적차이무통계학의의（P＞0.05），단재Ⅰ기신암여Ⅱ～Ⅲ기신암지간PCDH10기인갑기화솔적차이유통계학의의（P＜0.05）。결론 PCDH10기인재신암조직중갑기화정도교고，고분기적신암가능구유경고적PCDH10기인갑기화솔，제시PCDH10기인갑기화가능여신암적발생발전유관。
Objective To examine the PCDH10 gene methylation status in renal cell carcinoma (RCC) and analyze its clinical significance. Methods Methylation-specific PCR (MSP) was applied to detect the PCDH10 gene methylation status in 5 RCC cell lines and 47 cases of RCC primary tumors. Patients' baseline demographics and pathological outcomes were collected and analyzed. Results PCDH10 gene methylation was observed in 2 of 5 RCC cell lines (40%) using MSP.Aberrant methylation status was further detected in 31 of 47 primary tumors (66.0%) and only 1 of 6 (16.7%) adjacent normal renal tissues showed methylation. Furthermore, PCDH10 gene methylation status was significantly associated with TNM classification between stageⅠand Ⅱ-Ⅲin patients with RCC (P<0.05), yet without any association (P>0.05) with gender, age, location, tumor diameters or Fuhrman grade. Conclusions To our knowledge, we report for the first time that the aberrant hypermethylation of PCDH10 gene is often detected in RCC cell lines and primary tumors, which is also relevant to the more advanced tumor TNM classification. Thus, we conclude that PCDH10 gene methylation may be related to tumorigenesis and progression of RCC.